Interaction of Estrogen and Progesterone Receptors, and Human Epithelial Receptor 2, with Breast cancer Risk factors: a Multi-center case-only study in Iran
-
Rahim Akrami
,
Reza Ghiasvand
,
Akbar Fotouhi
,
Iraj Harirchi
,
Abbas Rezaianzadeh
,
Abdolrasoul Talei
,
Asiie Olfatbakhsh
,
Fatemeh Homaei Shandiz
,
Kazem Zendehdel
Abstract
Background: The etiology of breast cancer and our understanding on the carcinogenicity of different risk factors is impotant for control programms. We investigated the expression of estrogen and progesterone receptors (ER, PR), and human epithelial receptor 2 (HER2) overexpression and its associations, with environmental risk factors among breast cancer patients.Methods: We classified the patients into four groups including; triple negative (ER–/ PR–/HER2–), HER2-overexpression (ER–/PR–/HER2+), luminal A (ER+ and/or PR+/HER2–) and luminal B (ER+ and/or PR+/HER2+). We used a case-only design and multinomial logistic regression analyses.Results: In premenopausal patients, those with high BMI had lower prevalence of luminal B tumors compared to luminal A groups (OR= 0.42, 95% CI= 0.23 to 0.74). However, in the postmenopausal groups, prevalence of the luminal B tumors was less than luminal A tumors oral contraceptive pill (OCP) users (OR= 0.64, 95% CI= 0.42 to 0.98). In addition, among those who had an older age at menarche had a higher risk of ER2-overexpression tumors compared to luminal A tumors (OR= 2.82, 95% CI= 1.29-6.19).Conclusion: Expression of HER2, ER, and PR, among breast cancer patients seems to be associated with OCP use, BMI, age at menarche and age at first pregnancy.Ferlay J, Shin HR, Bray F, Forman D, Mathers C and Parkin DM: Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 127: 2893-2917, 2010.
Anderson WF, Chu KC, Chang S and Sherman ME: Comparison of Age-Specific Incidence Rate Patterns for Different Histopathologic Types of Breast Carcinoma. Cancer Epidemiol Biomarkers Prev 13: 1128-1135, 2004.
Aghajani H: Iranian Annual Of National Cancer Registration Report Center For Disease Control Prevention Noncommunicable. Journal 2008_2009.
Ferlay J, Shin HR, Bray F, Forman D, and MC and DM P: GLOBOCAN 2008, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 10 [Internet]. Lyon, France: International Agency for Research on Cancer; 2010. Available from: http://globocan.iarc.fr.
Huang C-S, Lin C-H, Lu Y-S and Shen C-Y: Unique features of breast cancer in Asian women--Breast cancer in Taiwan as an example. J Steroid Biochem Mol Biol 118: 300-303,
Althuis MD, Fergenbaum JH, Garcia-Closas M, Brinton LA, Madigan MP and Sherman ME: Etiology of Hormone Receptor–Defined Breast Cancer: A Systematic Review of the Literature. Cancer Epidemiology Biomarkers & Prevention 13: 1558-1568, 2004.
Dolle JM, Daling JR, White E, et al: Risk factors for triple-negative breast cancer in women under the age of 45 years. Cancer Epidemiol Biomarkers Prev 18: 1157-1166, 2009.
Brenton JD, Carey LA, Ahmed AA and Caldas C: Molecular classification and molecular forecasting of breast cancer: ready for clinical application? J Clin Oncol 23: 7350, 2005.
Potter JD, Cerhan JR, Sellers TA, et al: Progesterone and estrogen receptors and mammary neoplasia in the Iowa Women's Health Study: how many kinds of breast cancer are there? Cancer Epidemiology Biomarkers & Prevention 4: 319-326, 1995.
Huang W-Y, Newman B, Millikan RC, Schell MJ, Hulka BS and Moorman PG: Hormone-related Factors and Risk of Breast Cancer in Relation to Estrogen Receptor and Progesterone Receptor Status. Am J Epidemiol 151: 703-714, 2000.
Brown M, Tsodikov A, Bauer KR, Parise CA and Caggiano V: The role of human epidermal growth factor receptor 2 in the survival of women with estrogen and progesterone receptor-negative, invasive breast cancer: the California Cancer Registry, 1999-2004. Cancer 112: 737-747, 2008.
Bauer KR, Brown M, Cress RD, Parise CA and Caggiano V: Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California cancer Registry. Cancer 109: 1721-1728, 2007.
Rakha EA, El-Rehim DA, Paish C, et al: Basal phenotype identifies a poor prognostic subgroup of breast cancer of clinical importance. Eur J Cancer 42: 3149-3156, 2006.
Cleator S, Heller W and Coombes RC: Triple-negative breast cancer: therapeutic options. Lancet Oncol 8: 235, 2007.
Dey S, Boffetta P, Mathews A, Brennan P, Soliman A and Mathew A: Risk factors according to estrogen receptor status of breast cancer patients in Trivandrum, South India. Int J Cancer 125: 1663-1670, 2009.
Lipworth L, Bailey LR and Trichopoulos D: History of Breast-Feeding in Relation to Breast Cancer Risk: a Review of the Epidemiologic Literature. J Natl Cancer Inst 92: 302-312, 2000.
Xing P, Li J and Jin F: A case-control study of reproductive factors associated with subtypes of breast cancer in Northeast China. Med Oncol 27: 926-931, 2010.
Yavari P, Mosavizadeh M, Sadrol-Hefazi B and Mehrabi Y: Reproductive characteristics and the risk of breast cancer--a case-control study in Iran. Asian Pac J Cancer Prev 6: 370-375, 2005.
Ghiasvand R, Maram ES, Tahmasebi S and Tabatabaee SHR: Risk factors for breast cancer among young women in southern Iran. Int J Cancer 129: 1443-1449, 2011.
Ebrahimi M, Vahdaninia M and Montazeri A: Risk factors for breast cancer in Iran: a case-control study. Breast Cancer Res 4: 1 - 4, 2002.
Kwan ML, Kushi LH, Weltzien E, et al: Epidemiology of breast cancer subtypes in two prospective cohort studies of breast cancer survivors. Breast Cancer Res 11: R31, 2009.
Yang XR, Chang-Claude J, Goode EL, et al: Associations of breast cancer risk factors with tumor subtypes: a pooled analysis from the Breast Cancer Association Consortium studies. J Natl Cancer Inst 103: 250-263, 2011.
Nagata C, Matsushita Y and Shimizu H: Prevalence of hormone replacement therapy and user's characteristics: a community survey in Japan. Maturitas 25: 201-207, 1996.
Yu-Tang G, Xiao-Ou S, Qi D, et al: Association of menstrual and reproductive factors with breast cancer risk: Results from the Shanghai breast cancer study. Int J Cancer 87: 295-300, 2000.
Hajar S: Risk factors of osteoporosis in women over 50 years of age: a population based study in the north of Iran. Europe 9: 2008.
Devi CR, Tang TS and Corbex M: Incidence and risk factors for breast cancer subtypes in three distinct South-East Asian ethnic groups: Chinese, Malay and natives of Sarawak, Malaysia. Int J Cancer 131: 2869-2877, 2012.
Tan YO, Han S, Lu YS, et al: The prevalence and assessment of ErbB2‐positive breast cancer in Asia. Cancer 116: 5348-5357, 2010.
Sauter G, Lee J, Bartlett JM, Slamon DJ and Press MF: Guidelines for human epidermal growth factor receptor 2 testing: biologic and methodologic considerations. J Clin Oncol 27: 1323-1333, 2009.
Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A and McGuire WL: Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235: 177-182, 1987.
Gatto NM, Campbell UB, Rundle AG and Ahsan H: Further development of the case-only design for assessing gene–environment interaction: evaluation of and adjustment for bias. Int J Epidemiol 33: 1014-1024, 2004.
Perez EA, Suman VJ, Davidson NE, et al: HER2 testing by local, central, and reference laboratories in specimens from the North Central Cancer Treatment Group N9831 intergroup adjuvant trial. J Clin Oncol 24: 3032-3038, 2006.
Jacobs TW, Gown AM, Yaziji H, Barnes MJ and Schnitt SJ: Specificity of HercepTest in determining HER-2/neu status of breast cancers using the United States Food and Drug Administration–approved scoring system. J Clin Oncol 17: 1983-1983, 1999.
Thomson TA, Hayes MM, Spinelli JJ, et al: HER-2/neu in breast cancer: interobserver variability and performance of immunohistochemistry with 4 antibodies compared with fluorescent in situ hybridization. Mod Pathol 14: 1079-1086, 2001.
Millikan RC, Newman B, Tse CK, et al: Epidemiology of basal-like breast cancer. Breast Cancer Res Treat 109: 123-139, 2008.
Redondo CM, Gago-Domínguez M, Ponte SM, et al: Breast Feeding, Parity and Breast Cancer Subtypes in a Spanish Cohort. PLoS ONE 7: e40543, 2012.
Begg CB and Zhang Z: Statistical analysis of molecular epidemiology studies employing case-series. Cancer Epidemiology Biomarkers & Prevention 3: 173-175, 1994.
Begg CB and Zabor EC: Detecting and Exploiting Etiologic Heterogeneity in Epidemiologic Studies. Am J Epidemiol 176: 512-518, 2012.
| Files | ||
| Issue | Vol 8 No 1&2 (2016) | |
| Section | Original Articles | |
| Keywords | ||
| Breast Cancer Estrogen Receptor Progesterone Receptor HER2 Risk Factors | ||
| Rights and permissions | |
|
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
